Molluscum contagiosum: what's new and true?
Coloe
Jacquelyn
J
Ohio State University College of Medicine, Columbus, Ohio, USA. jcoloe@gmail.com
Burkhart
Craig N
CN
Morrell
Dean S
DS
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000279:Administration, Cutaneous; D000982:Antipruritics / Q000627:therapeutic use; D002193:Cantharidin / Q000627:therapeutic use; D002648:Child; D003876:Dermatitis, Atopic / Q000150:complications; D003937:Diagnosis, Differential; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007509:Irritants / Q000627:therapeutic use; D007641:Keratolytic Agents / Q000627:therapeutic use; D008976:Molluscum Contagiosum / Q000175:diagnosis / Q000188:drug therapy* / Q000517:prevention & control* / Q000821:virology; D017060:Patient Satisfaction; D011212:Poxviridae / Q000302:isolation & purification; D012307:Risk Factors; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D000982:Antipruritics; D005938:Glucocorticoids; D007509:Irritants; D007641:Keratolytic Agents; D002193:Cantharidin